|

Why I’m More Excited About MindMed’s 18-MC than its LSD treatments

ByPsychedelic Spotlight

Happy Holidays guys! I 🎄🙃 In this episode we’ll cover the many reasons why I’m more excited about MindMed’s 18-MC than its LSD treatments. As I mentioned in my previous video, the unfortunate fact is that the world is dealing with a second hidden epidemic: The Opioid Crisis. MindMed ( MMED/ MMEDF ) has a solution: 18-MC. Yes, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. However, this psychedelic medicines company has its own proprietary compound (18-MC) to treat addiction which, if successful, cannot be copied by the upcoming competition. Keep watching to learn more about MindMed’s plan to end the opioid crisis with 18-MC. We may have a light at the end of the tunnel, and MindMed could potentially defeat the opioid epidemic threat, making MMED one of the best stocks for 2021.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF
#mindmedstock

Similar Posts

  • This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]

    Listen, Videos

    In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.

    We will cover the latest developments in the field writ large.
    This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

    Timestamps:
    0:00 – Intro
    0:32 – Norway Decriminalization Bill
    1:59 – Psychedelic Market Stats
    3:21 – Magic Mushrooms to Treat Obesity
    5:40 – Ketamine to Treat Suicidal Thoughts?
    7:09 -The Acid King?
    8:58 – MindMed (MMED/MMEDF/MMQ) Updates
    10:04 – Compass Pathways (CMPS) Updates
    11:44 – Atai Life Sciences Updates
    14:02 – Numinus (NUMI) Updates
    15:13 – CYBIN Updates

    So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

  • Speculating on The Future of MindMed [Big News for MMED/MMEDF STOCK]

    Listen, Videos

    Hello back Psychedelic Investors! In this video we are going to be entering the Speculation Zone to discuss the implications of several of MindMed’s most recent moves. Aka, we shall be Speculating on The Future of MindMed [Big News for MMED/MMEDF STOCK].

    Timestamps:
    0:00 – Intro
    2:52 – Speculating on LSD Trials
    7:44 – MindMed’s Partnership Meaning
    13:45 – Nasdaq Uplisting

    This is actually the second video being released today. Earlier we posted a video detailing the three most recent press releases distributed by MindMed, where we explained what each move meant. If you haven’t seen that episode yet and want to get a detailed explanation of each Press Release before watching this video speculating on that information, you should probably do that first!

    Well actually, MindMed has since released another press release since the first video was filmed, on the commencement of their LSD Neutraliser phase 1 clinical trial.
    In our Video on MindMed’s Latest News, we discussed:

    1. How MindMed has started a phase 1 clinical trial studying the effects of mixing LSD and MDMA;
    2. We examined MindMed’s changes in Leadership, where JR Rahn became the sole CEO, and a gentleman by the name of Dr. Glick left the board;
    3. We also talked about MindMed’s new partnership with a company called MindShift Compounds AG, which is developing novel compounds owned exclusively by MMED.

    In this video, we discuss/SPECULATE on all of MindMed’s latest changes and how some of them could potentially influence the MMED/MMEDF stock’s uplisting on NASDAQ.

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video by Pressmaster from Pexels

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMEDF #MindmedStock